|
EP2471924A1
(en)
|
2004-05-28 |
2012-07-04 |
Asuragen, INC. |
Methods and compositions involving microRNA
|
|
ES2534300T3
(es)
|
2004-11-12 |
2015-04-21 |
Asuragen, Inc. |
Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
|
|
US8592384B2
(en)
|
2005-04-04 |
2013-11-26 |
The Board Of Regents Of The University Of Texas System |
Micro-RNA's that regulate muscle cells
|
|
CA2664383C
(en)
*
|
2006-09-19 |
2017-08-22 |
Asuragen, Inc. |
Micrornas differentially expressed in pancreatic diseases and uses thereof
|
|
CN101827941B
(zh)
*
|
2007-04-30 |
2014-07-16 |
俄亥俄州立大学研究基金会 |
用于区分胰腺癌与正常胰腺功能和/或慢性胰腺炎的方法
|
|
US8361714B2
(en)
|
2007-09-14 |
2013-01-29 |
Asuragen, Inc. |
Micrornas differentially expressed in cervical cancer and uses thereof
|
|
WO2009062169A2
(en)
|
2007-11-09 |
2009-05-14 |
The Board Of Regents Of The University Of Texas System |
Micro-rnas of the mir-15 family modulate cardiomyocyte survival and cardiac repair
|
|
WO2009070805A2
(en)
|
2007-12-01 |
2009-06-04 |
Asuragen, Inc. |
Mir-124 regulated genes and pathways as targets for therapeutic intervention
|
|
WO2009117418A2
(en)
|
2008-03-17 |
2009-09-24 |
The Board Of Regents Of The University Of Texas System |
Identification of micro-rnas involved in neuromuscular synapse maintenance and regeneration
|
|
US8258111B2
(en)
|
2008-05-08 |
2012-09-04 |
The Johns Hopkins University |
Compositions and methods related to miRNA modulation of neovascularization or angiogenesis
|
|
JP2012507300A
(ja)
|
2008-10-30 |
2012-03-29 |
カリス ライフ サイエンシズ ルクセンブルク ホールディングス |
Ｒｎａパターンを評価する方法
|
|
WO2010054386A2
(en)
*
|
2008-11-10 |
2010-05-14 |
Battelle Memorial Institute |
Methods, compositions, and devices utilizing microrna to determine physiological conditions
|
|
EP2350320A4
(en)
|
2008-11-12 |
2012-11-14 |
Caris Life Sciences Luxembourg Holdings |
METHOD AND SYSTEMS FOR USE OF EXOSOMES FOR THE DETERMINATION OF PHENOTYPES
|
|
US9074206B2
(en)
|
2008-11-13 |
2015-07-07 |
Fudan University |
Compositions and methods for micro-RNA expression profiling of colorectal cancer
|
|
AU2011223789A1
(en)
|
2010-03-01 |
2012-09-20 |
Caris Life Sciences Switzerland Holdings Gmbh |
Biomarkers for theranostics
|
|
KR20130043104A
(ko)
|
2010-04-06 |
2013-04-29 |
카리스 라이프 사이언스 룩셈부르크 홀딩스 |
질병용 순환 생물학적 지표들
|
|
WO2011150855A1
(en)
*
|
2010-06-04 |
2011-12-08 |
Fudan University |
Micro-rna biomarkers and methods for diagnosis of early colorectal carcinoma and high-grade adenoma
|
|
EP2591106A1
(en)
|
2010-07-06 |
2013-05-15 |
InteRNA Technologies B.V. |
Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
|
|
CA2812650C
(en)
*
|
2010-09-27 |
2019-11-05 |
Sabanci Universitesi |
Use of mirnas for the diagnosis, prophylaxis, treatment and follow-up of diseases involving macroautophagy abnormalities
|
|
EP2474617A1
(en)
|
2011-01-11 |
2012-07-11 |
InteRNA Technologies BV |
Mir for treating neo-angiogenesis
|
|
US9644241B2
(en)
|
2011-09-13 |
2017-05-09 |
Interpace Diagnostics, Llc |
Methods and compositions involving miR-135B for distinguishing pancreatic cancer from benign pancreatic disease
|
|
US9850541B2
(en)
|
2011-12-19 |
2017-12-26 |
Valley Health System |
Methods and kits for detecting subjects at risk of having cancer
|
|
WO2013101783A2
(en)
|
2011-12-30 |
2013-07-04 |
Bio-Rad Laboratories, Inc. |
Methods and compositions for performing nucleic acid amplification reactions
|
|
US9334498B2
(en)
|
2012-05-10 |
2016-05-10 |
Uab Research Foundation |
Methods and compositions for modulating MIR-204 activity
|
|
US9163235B2
(en)
|
2012-06-21 |
2015-10-20 |
MiRagen Therapeutics, Inc. |
Inhibitors of the miR-15 family of micro-RNAs
|
|
US20150344961A1
(en)
*
|
2012-09-11 |
2015-12-03 |
New York University |
Sera Based miRNAs as Non-Invasive Biomarkers in Melanoma
|
|
WO2014093924A1
(en)
|
2012-12-13 |
2014-06-19 |
Moderna Therapeutics, Inc. |
Modified nucleic acid molecules and uses thereof
|
|
PT2922554T
(pt)
|
2012-11-26 |
2022-06-28 |
Modernatx Inc |
Arn modificado nas porções terminais
|
|
DK3363902T3
(da)
*
|
2012-12-06 |
2020-01-02 |
Sigma Aldrich Co Llc |
Crispr-baseret genommodifikation og -regulering
|
|
EP3434774A1
(en)
|
2013-01-17 |
2019-01-30 |
ModernaTX, Inc. |
Signal-sensor polynucleotides for the alteration of cellular phenotypes
|
|
KR101501562B1
(ko)
*
|
2013-04-05 |
2015-03-11 |
연세대학교 산학협력단 |
췌장암 진단 마커를 검출하는 방법
|
|
US20150018230A1
(en)
*
|
2013-06-11 |
2015-01-15 |
Indiana University Research And Technology Corp. |
PLASMA miRNA SIGNATURE FOR THE ACCURATE DIAGNOSIS OF PANCREATIC DUCTAL ADENOCARCINOMA
|
|
JP6611411B2
(ja)
*
|
2013-12-05 |
2019-11-27 |
東レ株式会社 |
膵臓がんの検出キット及び検出方法
|
|
EP3108012A4
(en)
|
2014-02-18 |
2017-10-11 |
Baylor Research Institute |
Mir-320e and colorectal cancer
|
|
WO2015133477A1
(ja)
|
2014-03-04 |
2015-09-11 |
国立大学法人広島大学 |
膵がんの検出を補助する方法
|
|
JP6797017B2
(ja)
|
2014-05-30 |
2020-12-09 |
東レ株式会社 |
膵臓がんの検出キット又はデバイス及び検出方法
|
|
US9623040B2
(en)
|
2014-07-14 |
2017-04-18 |
The Board Of Trustees Of The Leland Stanford Junior University |
Immunomodulation by controlling expression levels of microRNAs in dendritic cells
|
|
EP3461904A1
(en)
|
2014-11-10 |
2019-04-03 |
ModernaTX, Inc. |
Alternative nucleic acid molecules containing reduced uracil content and uses thereof
|
|
JP2016123340A
(ja)
*
|
2014-12-26 |
2016-07-11 |
株式会社エバンス |
膵癌治療感受性の診断方法及び膵癌治療感受性の増強剤
|
|
EP3405579A1
(en)
|
2016-01-22 |
2018-11-28 |
Modernatx, Inc. |
Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
|
|
KR102574024B1
(ko)
|
2016-03-31 |
2023-09-04 |
국립연구개발법인 고쿠리츠간켄큐센터 |
조기 췌장암 또는 췌장암 전구 병변의 검출 키트 또는 디바이스 및 검출 방법
|
|
WO2017180587A2
(en)
|
2016-04-11 |
2017-10-19 |
Obsidian Therapeutics, Inc. |
Regulated biocircuit systems
|
|
PL3458083T3
(pl)
|
2016-05-18 |
2023-03-13 |
Modernatx, Inc. |
Polinukleotydy kodujące interleukinę-12 (il12) i ich zastosowania
|
|
EP3468537A1
(en)
|
2016-06-14 |
2019-04-17 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
JP2019518063A
(ja)
*
|
2016-06-20 |
2019-06-27 |
クラ オンコロジー， インコーポレイテッド |
Ｅｒｋ阻害剤を用いた扁平上皮細胞癌の処置
|
|
CA3029119A1
(en)
|
2016-06-29 |
2018-01-04 |
Crispr Therapeutics Ag |
Materials and methods for treatment of friedreich ataxia and other related disorders
|
|
WO2018002762A1
(en)
|
2016-06-29 |
2018-01-04 |
Crispr Therapeutics Ag |
Materials and methods for treatment of amyotrophic lateral sclerosis (als) and other related disorders
|
|
US11427838B2
(en)
|
2016-06-29 |
2022-08-30 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of myotonic dystrophy type 1 (DM1) and other related disorders
|
|
EP4650364A3
(en)
|
2016-07-06 |
2026-01-21 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of pain related disorders
|
|
EP3481857B1
(en)
|
2016-07-06 |
2026-02-11 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of pain related disorders
|
|
CA3042015A1
(en)
|
2016-10-26 |
2018-05-03 |
Modernatx, Inc. |
Messenger ribonucleic acids for enhancing immune responses and methods of use thereof
|
|
US11584932B2
(en)
|
2016-11-01 |
2023-02-21 |
The Research Foundation For The State University Of New York |
5-halouracil-modified microRNAs and their use in the treatment of cancer
|
|
EP3538067A1
(en)
|
2016-11-08 |
2019-09-18 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
MX2019009070A
(es)
|
2017-02-01 |
2019-10-30 |
Modernatx Inc |
Composiciones de arnm terapeuticas inmunomoduladoras que codifican peptidos de mutacion de oncogenes de activacion.
|
|
WO2018154462A2
(en)
|
2017-02-22 |
2018-08-30 |
Crispr Therapeutics Ag |
Materials and methods for treatment of spinocerebellar ataxia type 2 (sca2) and other spinocerebellar ataxia type 2 protein (atxn2) gene related conditions or disorders
|
|
AU2018224387B2
(en)
|
2017-02-22 |
2024-08-08 |
Crispr Therapeutics Ag |
Compositions and methods for gene editing
|
|
WO2018154439A1
(en)
|
2017-02-22 |
2018-08-30 |
Crispr Therapeutics Ag |
Materials and methods for treatment of spinocerebellar ataxia type 1 (sca1) and other spinocerebellar ataxia type 1 protein (atxn1) gene related conditions or disorders
|
|
EP3585899A1
(en)
|
2017-02-22 |
2020-01-01 |
CRISPR Therapeutics AG |
Materials and methods for treatment of primary hyperoxaluria type 1 (ph1) and other alanine-glyoxylate aminotransferase (agxt) gene related conditions or disorders
|
|
WO2018154418A1
(en)
|
2017-02-22 |
2018-08-30 |
Crispr Therapeutics Ag |
Materials and methods for treatment of early onset parkinson's disease (park1) and other synuclein, alpha (snca) gene related conditions or disorders
|
|
US20200131498A1
(en)
|
2017-06-14 |
2020-04-30 |
Modernatx, Inc. |
Polynucleotides encoding methylmalonyl-coa mutase
|
|
AU2018301704A1
(en)
|
2017-07-14 |
2020-03-05 |
Cofactor Genomics, Inc. |
Immuno-oncology applications using next generation sequencing
|
|
MX2020002348A
(es)
|
2017-08-31 |
2020-10-08 |
Modernatx Inc |
Métodos de elaboración de nanopartículas lipídicas.
|
|
EP3714055A1
(en)
|
2017-11-21 |
2020-09-30 |
CRISPR Therapeutics AG |
Materials and methods for treatment of autosomal dominant retinitis pigmentosa
|
|
EP3725881A1
(en)
*
|
2017-12-13 |
2020-10-21 |
Hiroshima University |
Method for aiding detection of pancreatic cancer
|
|
AU2018393050A1
(en)
|
2017-12-21 |
2020-06-18 |
Bayer Healthcare Llc |
Materials and methods for treatment of Usher Syndrome Type 2A
|
|
US20190314291A1
(en)
|
2018-01-30 |
2019-10-17 |
Modernatx, Inc. |
Compositions and methods for delivery of agents to immune cells
|
|
US20210163928A1
(en)
|
2018-04-11 |
2021-06-03 |
Modernatx, Inc. |
Messenger rna comprising functional rna elements
|
|
US20220403001A1
(en)
|
2018-06-12 |
2022-12-22 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
|
US12090235B2
(en)
|
2018-09-20 |
2024-09-17 |
Modernatx, Inc. |
Preparation of lipid nanoparticles and methods of administration thereof
|
|
US20210386788A1
(en)
|
2018-10-24 |
2021-12-16 |
Obsidian Therapeutics, Inc. |
Er tunable protein regulation
|
|
CN113939282A
(zh)
|
2019-01-31 |
2022-01-14 |
摩登纳特斯有限公司 |
制备脂质纳米颗粒的方法
|
|
BR112021017744A2
(pt)
|
2019-03-08 |
2021-11-16 |
Obsidian Therapeutics Inc |
Composições e métodos de cd40l para regulação ajustável
|
|
WO2020218489A1
(ja)
*
|
2019-04-26 |
2020-10-29 |
国立大学法人大阪大学 |
トンネル電流を使用したマイクロｒｎａ解析
|
|
MA56517A
(fr)
|
2019-06-24 |
2022-04-27 |
Modernatx Inc |
Arn messager comprenant des éléments d'arn fonctionnels et leurs utilisations
|
|
EP3987027A1
(en)
|
2019-06-24 |
2022-04-27 |
ModernaTX, Inc. |
Endonuclease-resistant messenger rna and uses thereof
|
|
WO2021046451A1
(en)
|
2019-09-06 |
2021-03-11 |
Obsidian Therapeutics, Inc. |
Compositions and methods for dhfr tunable protein regulation
|
|
US20230285297A1
(en)
|
2020-01-31 |
2023-09-14 |
Modernatx, Inc. |
Methods of preparing lipid nanoparticles
|
|
US11965162B2
(en)
*
|
2020-04-16 |
2024-04-23 |
The Johns Hopkins University |
MicroRNA and inhibitors thereof and methods of treatment
|
|
WO2021262919A2
(en)
|
2020-06-26 |
2021-12-30 |
The Research Foundation For The State University Of New York |
5-halouracil-modified micrornas and their use in the treatment of cancer
|
|
US12630881B2
(en)
|
2020-07-16 |
2026-05-19 |
Kurume University |
Use of microRNA as pancreatic cancer biomarker
|
|
JP2023535225A
(ja)
|
2020-07-24 |
2023-08-16 |
ストランド セラピューティクス インコーポレイテッド |
改変ヌクレオチドを含む脂質ナノ粒子
|
|
TW202220637A
(zh)
|
2020-08-06 |
2022-06-01 |
美商現代公司 |
製備脂質奈米顆粒之方法
|
|
KR20230129479A
(ko)
|
2021-01-08 |
2023-09-08 |
스트랜드 세러퓨틱스 인코포레이티드 |
발현 구성체 및 이의 용도
|
|
CA3171589A1
(en)
|
2021-05-03 |
2022-11-03 |
Moritz THRAN |
Improved nucleic acid sequence for cell type specific expression
|
|
WO2023166425A1
(en)
|
2022-03-01 |
2023-09-07 |
Crispr Therapeutics Ag |
Methods and compositions for treating angiopoietin-like 3 (angptl3) related conditions
|
|
AU2023262576A1
(en)
|
2022-04-26 |
2024-10-10 |
Strand Therapeutics Inc. |
Lipid nanoparticles comprising venezuelan equine encephalitis (vee) replicon and uses thereof
|
|
WO2024026475A1
(en)
|
2022-07-29 |
2024-02-01 |
Modernatx, Inc. |
Compositions for delivery to hematopoietic stem and progenitor cells (hspcs) and related uses
|
|
WO2024026487A1
(en)
|
2022-07-29 |
2024-02-01 |
Modernatx, Inc. |
Lipid nanoparticle compositions comprising phospholipid derivatives and related uses
|
|
US20250375391A1
(en)
|
2022-07-29 |
2025-12-11 |
Modernatx, Inc. |
Lipid nanoparticle compositions comprising surface lipid derivatives and relates uses
|
|
CN121079317A
(zh)
|
2023-04-28 |
2025-12-05 |
深圳深信生物科技有限公司 |
经修饰的递送载体及其应用
|
|
WO2024259373A1
(en)
|
2023-06-14 |
2024-12-19 |
Modernatx, Inc. |
Compounds and compositions for delivery of therapeutic agents
|
|
WO2025160381A1
(en)
|
2024-01-26 |
2025-07-31 |
Modernatx, Inc. |
Methods of preparing lipid nanoparticles
|
|
WO2025166202A1
(en)
|
2024-01-31 |
2025-08-07 |
Modernatx, Inc. |
Lipid nanoparticle compositions comprising sialic acid derivatives and the uses thereof
|
|
CN122180503A
(zh)
|
2024-04-30 |
2026-06-09 |
深圳深信生物科技有限公司 |
脂质纳米颗粒及其应用
|
|
ES3048857A1
(es)
*
|
2024-06-10 |
2025-12-11 |
Fundacion Para La Investig E Innovacion Biosanitaria Del Principado De Asturias Finba |
FIRMA DE miRNA UTILES EN LA DISCRIMINACION DE TUMORES
|
|
CN119391860B
(zh)
*
|
2024-12-25 |
2025-03-21 |
慧算基因科技(上海)有限公司 |
一种用于胰腺癌术后mrd检测及动态监测的引物探针组合物、试剂盒及应用
|